<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00612755</url>
  </required_header>
  <id_info>
    <org_study_id>Extrados</org_study_id>
    <secondary_id>2004-004948-45</secondary_id>
    <nct_id>NCT00612755</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety to Extend Treatment 24 Weeks in co-Infected HIV-HCV Genotype 1 and/or 4</brief_title>
  <official_title>Open, Randomized, Multicenter Phase IV Study to Evaluate Efficacy and Safety to Extend Treatment 24 Weeks in co-Infected HIV-HCV Patients Genotype 1 and/or 4</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinico Universitario San Cecilio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinico Universitario San Cecilio</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study concerning viral kinetic with 10 co-infected HIV-HCV patients on treatment with
      peginterferon alfa-2a + ribavirin o IFN + ribavirin was reported in Conference on
      Retroviruses and Opportunistic Infections 2002 by Dr. Torriani shown half-life of HCV virions
      and the viral clearance was larger than mono-infected patients.

      The doubt is if this difference in viral kinetic of HIV-HCV co-infected patients versus
      mono-infected is related with the loss of profited on treatment.

      In the APRICOT trial patients genotype 2/3 were treated for 48 weeks and the relapse rates
      was only 2%.

      The present study want to evaluate is the treatment extent for 24 weeks more in patients
      genotype 1 and/or 4 will be improve the percentage of patients with viral clearance at the
      end of the follow-up period, to prevent relapsed in patients with response at the end of
      treatment.

      Patients will be randomized to received 180 µg/week of peginterferon alfa-2a + 1000-1200
      mg/day of ribavirin during 24 weeks more or control.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate efficacy of extend treatment during 24 weeks more in co-infected HIV-HCV patients
      with genotype 1 and/or 4 who at 44 week of treatment with peginterferón alfa-2a in
      combination with ribavirin have RNA-HCV undetectable.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>% of patients with RNA-HCV undetectable</measure>
    <time_frame>at 48 week of study (24 weeks after the end of treatment period of trial).</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>% of percentage of patients with RNA-HCV undetectable</measure>
    <time_frame>24 weeks of trial period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>HIV Infections</condition>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peginterferon alfa-2a 180 mcg/week + 1000-1200 mg/day ribavirin during 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa-2a + ribavirin</intervention_name>
    <description>Peginterferon alfa-2a 180 mcg/week ribavirin 1000-1200 mg/day during 24 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Pegasys</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients on treatment with Peginterferon alfa-2a (180 µg/week) in combination with
             Ribavirin (1000-1200 mg/day) who are RNA-HCV undetectable at 44 week

          -  RNA-HCV positive at 48 week before study and genotype 1 or 4.

          -  HIV-1 positive: ELISA y Western-blot.

          -  Stable status of HIV-1 infection in the opinion of the investigator, (patients who are
             not expected to progress during the study).

          -  Negative urine or blood pregnancy test (for women of childbearing potential)
             documented within the 24-hour period prior to the first dose of study drug.
             Additionally, all fertile males and females must be using two forms of effective
             contraception during treatment and during the 6 months after treatment end. This may
             include, but is not limited to, using birth control pills, IUDs, condoms, diaphragms,
             or implants, being surgically sterilized, or being in a post-menopausal state.

          -  Willingness to give written informed consent and willingness to participate to and
             comply with the study.

        Exclusion Criteria:

          -  Patients with RNA-HCV detectable after 44 weeks of treatment with Peginterferon
             alfa-2a (180 µg/week) in combination with Ribavirin (1000-1200 mg/day).

          -  Patients with other treatment for chronic hepatitis, different which of inclusion
             criteria is described.

          -  More of tree weeks from the end of treatment with Peginterferon alfa-2a (180 µg/week)
             in combination with Ribavirin (1000-1200 mg/day) to the inclusion in &quot;EXTRADOS&quot; trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José Hernández-Quero, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Clínico Universitario San Cecilio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de Txagorritxu</name>
      <address>
        <city>Vitoria</city>
        <state>Alava</state>
        <zip>01009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Bellvitge</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Jerez</name>
      <address>
        <city>Jerez de la Frontera</city>
        <state>Cádiz</state>
        <zip>11407</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Insular</name>
      <address>
        <city>Las Palmas</city>
        <state>Gran Canaria</state>
        <zip>35016</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Donostia</name>
      <address>
        <city>San Sebastián</city>
        <state>Guipúzcoa</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario</name>
      <address>
        <city>Santiago</city>
        <state>La Coruña</state>
        <zip>15705</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Hospital de Alcorcón</name>
      <address>
        <city>Alcorcón</city>
        <state>Madrid</state>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Son Dureta</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Mallorca</state>
        <zip>07014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta del Mar</name>
      <address>
        <city>Cádiz</city>
        <zip>11009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario San Cecilio</name>
      <address>
        <city>Granada</city>
        <zip>18013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Valme</name>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consorcio Hospital General</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <zip>47011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2008</study_first_submitted>
  <study_first_submitted_qc>January 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2008</study_first_posted>
  <last_update_submitted>January 29, 2008</last_update_submitted>
  <last_update_submitted_qc>January 29, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2008</last_update_posted>
  <responsible_party>
    <name_title>José Hernández-Quero</name_title>
    <organization>Hospital Clinico Universitario San Cecilio</organization>
  </responsible_party>
  <keyword>chronic hepatitis C</keyword>
  <keyword>co-infection</keyword>
  <keyword>extend treatment</keyword>
  <keyword>co-infected HIV-HCV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

